Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

“At the first prespecified interim analysis, Libtayo achieved a remarkably high bar in improving disease-free survival in high-risk cutaneous squamous cell carcinoma. With no currently approved ...

The EC approval also now means that Libtayo can be used to treat certain patients across four types of cancer within the European Union: advanced squamous cell carcinoma (SCC), advanced basal cell ...

The study enrolled women with squamous cell carcinoma and adenocarcinoma forms of cervical cancer, and the death rate in those subgroups was reduced by 27% and 44%, respectively, with Libtayo.

However, Regeneron recently announced that its PD-1 inhibitor LIBTAYO had met its primary endpoint among patients with high risk cutaneous squamous cell carcinoma (CSCC). This positive news in ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...